...
首页> 外文期刊>European journal of pharmaceutics and biopharmaceutics: official journal of Arbeitsgemeinschaft fuer Pharmazeutische Verfahrenstechnik e.V >Modified thermoresponsive Poloxamer 407 and chitosan sol-gels as potential sustained-release vaccine delivery systems
【24h】

Modified thermoresponsive Poloxamer 407 and chitosan sol-gels as potential sustained-release vaccine delivery systems

机译:改性热响应泊洛克马酯407和壳聚糖溶胶 - 凝胶作为潜在的缓释疫苗输送系统

获取原文
获取原文并翻译 | 示例

摘要

Thermoresponsive, particle-loaded, Poloxamer 407 (P407)-Pluronic-R (R) (25R4) or chitosan-methyl cellulose (MC) formulations were developed as single-dose, sustained release vaccines. The sol-gels, loaded either with a particulate vaccine (cubosomes) or soluble antigen (ovalbumin) and adjuvants (Quil A and monophosphoryl lipid A), were free-flowing liquids at room temperature and formed stable gels at physiological temperatures. Rheological results showed that both systems meet the criteria of being thermoresponsive gels. The P407-25R4 sol-gels did not significantly sustain the release of antigen in vivo while the chitosan-MC sol-gels sustained the release of antigen up to at least 14 days after administration. The chitosan-MC sol-gels stimulated both cellular and humoral responses. The inclusion of cubosomes in the sol-gels did not provide a definitive beneficial effect. Further analysis of the formulations with small-angle X-ray scattering (SAXS) revealed that while cubosomes were stable in chitosan-MC gels they were not stable in P407-25R4 formulations. The reason for the mixed response to cubosome-loaded vehicles requires more investigation, however it appears that the cubosomes did not facilitate synchronous vaccine release and may in fact retard release, reducing efficacy in some cases. From these results, chitosan-MC sol-gels show potential as sustained release vaccine delivery systems, as compared to the P407-25R4 system that had a limited ability to sustain antigen release. (C) 2014 Elsevier B.V. All rights reserved.
机译:热响应性,粒料,泊洛克敏407(P407)-Cluronic-R(R)(25r 4)或壳聚糖 - 甲基纤维素(MC)制剂作为单剂量,持续释放疫苗。用颗粒状疫苗(缔缔统计学)或可溶性抗原(卵烧蛋白)和佐剂(Quil A和单磷虾脂质A)负载的溶胶 - 凝胶在室温下是自由流动的液体,并在生理温度下形成稳定的凝胶。流变结果表明,两种系统都符合热响应凝胶的标准。 P407-25R4溶胶 - 凝胶没有显着维持体内抗原的释放,而壳聚糖-MC溶胶 - 凝胶在给药后至少14天释放抗原。壳聚糖-MC溶胶凝胶刺激了细胞和体液反应。在溶胶 - 凝胶中包含立方体并没有提供明确的有益效果。进一步分析具有小角度X射线散射(SAXS)的制剂,显示,虽然在壳聚糖-MC凝胶中稳定,但在P407-25R4制剂中不稳定。混合响应对卧室装载的车辆的原因需要更多的研究,但似乎立方体没有促进同步疫苗释放,并且可以在某些情况下降低疗效。从这些结果来看,壳聚糖-MC溶胶 - 凝胶显示潜在的持续释放疫苗递送系统,相比具有有限的维持抗原释放能力的P407-25R4系统。 (c)2014 Elsevier B.v.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号